Q&A: No­vo Nordisk Foun­da­tion’s Celler­a­tor CEO Thomas Carlsen digs in­to $135.4M Dan­ish cell ther­a­py fa­cil­i­ty

The No­vo Nordisk Foun­da­tion re­vealed Thurs­day it has com­mit­ted €127 mil­lion ($135.4 mil­lion) to build a new cell ther­a­py fa­cil­i­ty in Den­mark, which is set to be com­plet­ed by 2027.

The fa­cil­i­ty, Celler­a­tor, will be lo­cat­ed at the Tech­ni­cal Uni­ver­si­ty of Den­mark in Lyn­g­by, and will fa­cil­i­tate col­lab­o­ra­tion be­tween pub­lic and pri­vate com­pa­nies — in­clud­ing acad­e­mia, biotech and phar­ma com­pa­nies.

The site will fo­cus on the fi­nal de­vel­op­ment and up­scal­ing of cell ther­a­pies for dis­eases such as chron­ic heart fail­ure, Parkin­son’s dis­ease, type 1 di­a­betes and can­cer for use in clin­i­cal tri­als. It will sup­port ther­a­pies de­rived from em­bry­on­ic stem cells, in­duced pluripo­tent stem cells and adult stem cells.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER